InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Verheugen adds to Community patent momentum

James Nurton, Ljubljana


Patent protection in Europe is “cumbersome and costly” and there is an “urgent need” for both a Community patent and a solution to pan-European litigation, according to European Commission vice-president Günter Verheugen

His comments, made in a speech today at the European Patent Forum 2008 in Ljubljana, Slovenia, are the latest sign that momentum is building towards a Europe-wide agreement on patent reform.

Verheugen said that, following the introduction of the London...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

When are patent rights exhausted? Impression v Lexmark #SCOTUS arguments analysed by @mdloney… https://t.co/lpYyUR7luw

Mar 28 2017 03:46 ·  reply ·  retweet ·  favourite
ManagingIP profile

Background reading on SMU patents & cases for anyone attending tonight's @UNIONIP_UK Dinner! @gwilip @EIP_Elements… https://t.co/H4tkalJYzu

Mar 28 2017 03:42 ·  reply ·  retweet ·  favourite
ManagingIP profile

Less than 2 days to go until our next free webinar on IP in Asia with @inoviaIP @Minesoftnews - sign up here! https://t.co/gh3Ka8t9q1

Mar 28 2017 03:35 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements